ClinicalTrials.gg
TerminatedNCT04858425RESERVOIRUpdated Oct 8, 2024Results posted

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

A Phase 2 interventional study of Niclosamide and Placebo in Covid19, sponsored by Entero Therapeutics. Terminated at 25 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Entero Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
The termination of the study was a decision based on topline data analysis (no efficacy as per Day 43) of the study data.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
520th of 1,321
166 · median 91
Started
2021
with 503 others
Phase 2
349 of 1,859
14 open now
Registered
1,099th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 520th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 349 in phase 2, and was the 1,099th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with COVID-19 with gastrointestinal infection.

03

Conditions studied

  • Covid19

Browse trials for

Keywords

  • SARS-CoV-2
  • Covid
  • Covid19 Diarrhea
  • Covid19 GI Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Part 1 only, patients with a primary diagnosis of COVID-19, with or without pneumonia, who agree to be monitored daily for at least 7 days after randomization and who accept continuing to be assessed for the study procedures.
  2. Part 2 only, patients with a primary diagnosis of COVID-19, with or without pneumonia.

Exclusion criteria

Exclusion Criteria:

  1. At the time of randomization, patients who require intensive care unit (ICU) admission or patients with severe respiratory insufficiency who require mechanical ventilation or with rapid worsening of respiratory function leading to expectation for mechanical ventilation or ICU admission.
  2. Evidence of rapid clinical deterioration or existence of any life-threatening co-morbidity or any other medical condition that, in the opinion of the investigator, makes the patient unsuitable for inclusion.
  3. Patients who, at the time of enrollment, are not in a clinical condition compatible with the oral administration of the study drug.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Niclosamide

    Niclosamide tablets 400 mg 3 times daily for 14 days

    Drug: Niclosamide

  • Placebo comparator
    Placebo

    Matching placebo tablets 3 times daily for 14 days

    Drug: Placebo

Interventions

  • Niclosamide tablets 400 mg 3 times daily for 14 days

  • DrugPlacebo

    Matched placebo tablets 400 mg 3 times daily for 14 days

06

What researchers measure

Primary outcomes

  1. SAEs

    Serious adverse event (SAE) coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: Day 1 to 6 weeks

  2. TEAE

    Proportion of patients with Treatment Emergent Adverse Events (TEAE) leading to study drug discontinuation.

    Time frame: Day 1 to 6 weeks

  3. Fecal RNA Virus Clearance

    Time to fecal viral RNA clearance (stool sample) assessed by RT-qPCR in the niclosamide arm compared to the placebo arm.

    Time frame: Day 1 to 6 weeks

  4. Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Leukocytes and Platelets)

    Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.

    Time frame: Day 1 to Day 43

  5. Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Erythrocytes)

    Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Erythrocytes

    Time frame: Day 1 to Day 43

  6. Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemocrit)

    Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Hemocrit (L/L)

    Time frame: Day 1 to Day 43

  7. Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemoglobin)

    Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Hemoglobin (g/L)

    Time frame: Day 1 to Day 43

  8. Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Corpuscular Volume)

    Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Corpuscular volume (fL)

    Time frame: Day 1 to Day 43

  9. Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically BUN, Glucose, Chloride, Potassium, and Sodium)

    Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.

    Time frame: Day 1 to Day 43

  10. Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Alkaline Phosphatase, AST, ALT, and LDH)

    Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.

    Time frame: Day 1 to Day 43

  11. Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Bilirubin and Serum Creatinine)

    Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.

    Time frame: Day 1 to Day 43

07

Results

Posted Jul 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneNiclosamidePlacebo
Started8482
Completed7477
Not completed105
Withdrew: Adverse event22
Withdrew: Withdrawal by subject31
Withdrew: Lost to follow-up42
Withdrew: Lost to follow-up10

Outcome measures

PrimarySAEs

Serious adverse event (SAE) coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA).

Time frame:
Day 1 to 6 weeks
Reported as:
Number · participants
SAEs
participantsNiclosamidePlacebo
Infections and infestations01
Injury, poisoning and procedural complications01
PrimaryTEAE

Proportion of patients with Treatment Emergent Adverse Events (TEAE) leading to study drug discontinuation.

Time frame:
Day 1 to 6 weeks
Reported as:
Number · participants
TEAE
participantsNiclosamidePlacebo
Gastrointetinal disorders11
Blood and lymphatic system disorders01
Endocrine disorders01
Infections and infestations01
Injury, poisoning and procedural complications01
Investigations11
Musculoskeletal and connective tissue disorders01
PrimaryFecal RNA Virus Clearance

Time to fecal viral RNA clearance (stool sample) assessed by RT-qPCR in the niclosamide arm compared to the placebo arm.

Time frame:
Day 1 to 6 weeks
Reported as:
Number · participants
Fecal RNA Virus Clearance
participantsNiclosamidePlacebo
Day 489
Day 82120
Day 154033
Day 224842
Day 295143
Day 365145
Day 435248
PrimarySafety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Leukocytes and Platelets)

Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.

Time frame:
Day 1 to Day 43
Reported as:
Median · cells (10^9/L)
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Leukocytes and Platelets)
cells (10^9/L)NiclosamidePlacebo
Leukocytes0.340 (-12.71 to 4.38)0.495 (-11.13 to 5.70)
Platelets11.5 (-196 to 116)3.0 (-337 to 148)
PrimarySafety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Erythrocytes)

Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Erythrocytes

Time frame:
Day 1 to Day 43
Reported as:
Median · cells 10^12/L
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Erythrocytes)
cells 10^12/LNiclosamidePlacebo
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Erythrocytes)-0.250 (-0.87 to .85)-0.125 (-0.96 to 0.84)
PrimarySafety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemocrit)

Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Hemocrit (L/L)

Time frame:
Day 1 to Day 43
Reported as:
Median · L/L
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemocrit)
L/LNiclosamidePlacebo
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemocrit)-0.0195 (-0.100 to 0.077)-0.0130 (-0.141 to 0.072)
PrimarySafety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemoglobin)

Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Hemoglobin (g/L)

Time frame:
Day 1 to Day 43
Reported as:
Median · g/L
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemoglobin)
g/LNiclosamidePlacebo
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Hemoglobin)-4.0 (-30 to 13)-2.5 (-39 to 14)
PrimarySafety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Corpuscular Volume)

Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided. Corpuscular volume (fL)

Time frame:
Day 1 to Day 43
Reported as:
Median · fL
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Corpuscular Volume)
fLNiclosamidePlacebo
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Corpuscular Volume)-0.35 (-10.5 to 9.3)-0.75 (-16.1 to 15.8)
PrimarySafety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically BUN, Glucose, Chloride, Potassium, and Sodium)

Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.

Time frame:
Day 1 to Day 43
Reported as:
Median · mmol/L
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically BUN, Glucose, Chloride, Potassium, and Sodium)
mmol/LNiclosamidePlacebo
BUN0.000 (-6.07 to 4.65)0.000 (-8.21 to 3.21)
Glucose-0.360 (-5.22 to 3.28)0.110 (-9.15 to 3.28)
Chloride2.0 (-7 to 9)1.0 (-9 to 13)
Potassium0.00 (-1.0 to 1.1)0.10 (-1.9 to 2.1)
Sodium1.0 (-6 to 7)0.0 (-13 to 7)
PrimarySafety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Alkaline Phosphatase, AST, ALT, and LDH)

Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.

Time frame:
Day 1 to Day 43
Reported as:
Median · U/L
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Alkaline Phosphatase, AST, ALT, and LDH)
U/LNiclosamidePlacebo
Alkaline Phosphatase2.0 (-173 to 26)2.0 (-76 to 49)
AST-2.5 (-117 to 98)-1.0 (-151 to 26)
ALT-3.0 (-70 to 73)-4.0 (-77 to 32)
LDH-2.0 (-209 to 157)6.0 (-86 to 102)
PrimarySafety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Bilirubin and Serum Creatinine)

Change in safety laboratory tests, including CBC, BUN, blood sugar, electrolytes, alkaline phosphatase, AST, ALT, LDH, total bilirubin, serum creatinine, from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided.

Time frame:
Day 1 to Day 43
Reported as:
Median · mcmol/L
Safety Laboratory Tests Including CBC, BUN, Blood Sugar, Electrolytes (Specifically Bilirubin and Serum Creatinine)
mcmol/LNiclosamidePlacebo
Bilirubin0.60 (-10.7 to 10.1)1.20 (-4.3 to 22)
Creatinine0.0 (-53 to 44)0.0 (-44 to 27)

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niclosamide0/84 (0%)0/84 (0%)1/84 (1.2%)
Placebo0/82 (0%)2/82 (2.4%)1/82 (1.2%)
Most frequent serious events
Most frequent serious events
EventNiclosamidePlacebo
Infections and infestationsInfections and infestations0/841/82
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications0/841/82
Most frequent other events
Most frequent other events
EventNiclosamidePlacebo
Gastrointestinal disordersGastrointestinal disorders1/841/82
Blood and lymphatic system disordersBlood and lymphatic system disorders0/841/82
Endocrine disordersEndocrine disorders0/841/82
Infections and infestationsInfections and infestations0/841/82
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications0/841/82
InvestigationsInvestigations1/841/82
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders0/841/82

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)NiclosamidePlaceboTotal
<=18 years000
Between 18 and 65 years7774151
>=65 years7815
Sex: Female, Male
Sex: Female, Male(Participants)NiclosamidePlaceboTotal
Female474693
Male373673
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NiclosamidePlaceboTotal
Hispanic or Latino5563118
Not Hispanic or Latino291948
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NiclosamidePlaceboTotal
American Indian or Alaska Native000
Asian8513
Native Hawaiian or Other Pacific Islander437
Black or African American000
White7174145
More than one race000
Unknown or Not Reported101
08

Study locations

25 sites
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • Midland Florida Clinical Research Center, LLC
    DeLand, Florida 32720-0920, United States
  • New Generation Medical Research
    Hialeah, Florida 33016-1895, United States
  • LCC Medical Reserach Institute, LLC
    Miami, Florida 33126, United States
  • Westchester General Hospital
    Miami, Florida 33155-2805, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • P & S Research, LLC
    Miami, Florida 33175-2912, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • IACT Health - Roswell
    Columbus, Georgia 30076, United States
  • Snake River Research, PLLC
    Idaho Falls, Idaho 83404, United States
  • Homestead Associates in Research
    Homestead Meadows, Texas 33032-8225, United States
  • SMS Clinical Research LLC
    Mesquite, Texas 75149, United States
  • Tranquil Research
    Webster, Texas 77598, United States
  • Yashoda Hospital
    Secunderabad, Andhra Pradesh 50003, India
  • SSG Hospital and Medical Institute
    Vadodara, Gujarat 390001, India
  • GMERS Medical College and Hospital
    Vadodara, Gujarat 390021, India
  • Noble Hospital Private Limited
    Pune, Maharashtra 411013, India
  • Sir Ganga Ram Hospital
    Nagar, New Delhi 110060, India
  • Maharaja Agrasen Superspeciality Hospital, Jaipur
    Jaipur, Rajasthan 302039, India
  • Malla Reddy Narayana Multispecialty Hospital
    Hyderabad, Telangana 500055, India
  • Communal Non-Commercial Medical Enterprise "Likarnya Prydniprovska"
    Kremenchug, Poltava 39600, Ukraine
  • Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council
    Dnipro, 41102, Ukraine
  • Municipal Non-profit Enterprise Central City Clinical Hospital of Ivano-Frankivsk City Council
    Ivano-Frankivsk, 76025, Ukraine
  • Municipal Non-Profit Enterprise City Clinical Hospital 13 of Kharkiv Regional Council
    Kharkiv, 61124, Ukraine
  • Private Enterprise Private Manufacturing Company Acinus
    Kropyvnytskyi, 25006, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Jun 2022, 13 months.

Results were first posted in Jul 2024, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Apr 26, 2021
StartActual
Apr 30, 2021
Primary completionActual
Jun 4, 2022
CompletionActual
Sep 10, 2023
Results first posted
Jul 24, 2024
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04858425
Lead sponsor
Entero Therapeutics
Responsible party
Sponsor
First posted
Apr 26, 2021
Start date
Apr 30, 2021
Primary completion
Jun 4, 2022
Completion
Sep 10, 2023
Results posted
Jul 24, 2024
Last update
Oct 8, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niclosamide

Start the discussion